Short answer: Bioidentical hormone replacement therapy (BHRT) — using oestradiol and progesterone with the same molecular structure as the body’s own hormones — can help manage three metabolic consequences of menopause: accelerated bone loss, increased hepatic fat accumulation and unfavourable lipid profile changes. Clinical evidence supports oestrogen’s role in preserving bone mineral density, modulating hepatic lipid metabolism and improving HDL cholesterol, though the net effect depends on the specific hormone, dose, route and the patient’s baseline risk profile. In Malaysia, compounded BHRT is prepared on a registered doctor’s prescription under Good Compounding Practice (GCP), for one named patient.
The Three Metabolic Shifts at Menopause
Menopause — defined as 12 months after the final menstrual period — is marked by a steep decline in ovarian oestradiol production. This hormonal shift has consequences far beyond the reproductive system. Oestrogen receptors are expressed in bone, liver, adipose tissue, vascular endothelium and the brain, so the withdrawal of oestrogen affects multiple metabolic pathways simultaneously.
Three of the most clinically significant metabolic changes are:
- Bone: Accelerated bone resorption leading to loss of bone mineral density (BMD) and increased fracture risk
- Liver: Increased hepatic fat accumulation and higher risk of non-alcoholic fatty liver disease (NAFLD)
- Fats (lipids): Adverse shifts in the lipid profile — rising LDL cholesterol and triglycerides, falling HDL cholesterol
Each of these is modulated by oestrogen, which is why BHRT is clinically relevant beyond symptom management alone.
Bone: Oestrogen and Bone Mineral Density Preservation
Oestrogen inhibits osteoclast activity — the cells that resorb bone — through direct action on oestrogen receptors on bone cells and through regulation of RANK ligand (RANKL) and osteoprotegerin (OPG) signalling. When oestrogen levels fall at menopause, osteoclast activity increases, bone resorption outpaces formation, and BMD declines at an accelerated rate of 1–3% per year in the first five years after menopause.
A systematic review and network meta-analysis of fracture risk reduction by osteoporosis treatments in postmenopausal women confirmed that oestrogen-based therapies are among the effective options for preserving BMD and reducing fracture risk, with the greatest benefit observed when therapy is initiated within 10 years of menopause (Händel et al., BMJ, 2023; PMID 37130601). A separate network meta-analysis of pharmacological therapies for fracture prevention in postmenopausal women similarly identified oestrogen therapy as an established intervention for bone health (Barrionuevo et al., The Journal of Clinical Endocrinology and Metabolism, 2019; PMID 30907957).
For prescribers in Kuala Lumpur and the Klang Valley, the clinical implication is clear: for women who are appropriate candidates for hormone therapy, BHRT can serve a dual role — managing menopausal symptoms while preserving bone density. The bone benefit is dose-dependent and route-dependent; transdermal oestradiol at standard doses produces comparable bone preservation to oral oestrogen, with different effects on hepatic metabolism.
Liver: Oestrogen and Hepatic Fat Metabolism
The relationship between menopause and liver fat is increasingly recognised. Oestrogen receptors are expressed on hepatocytes, and oestrogen signalling influences hepatic lipid metabolism, insulin sensitivity and inflammation. Postmenopausal women have a higher prevalence of NAFLD compared with premenopausal women of the same age, and the decline in oestrogen is thought to be a contributing factor.
A meta-analysis and systematic review of randomised controlled trials examined the effect of transdermal 17β-oestradiol combined with norethisterone acetate treatment on the lipid profile in postmenopausal women, finding that hormone therapy produced measurable changes in hepatic lipid metabolism markers (Tao et al., Steroids, 2022; PMID 35688182). A randomised controlled trial comparing oral and transdermal short-term oestrogen therapy in postmenopausal women with metabolic syndrome found that the route of administration significantly affected metabolic outcomes, including hepatic lipid handling (Chu et al., Fertility and Sterility, 2006; PMID 17074346).
The clinical takeaway is that oestrogen therapy — particularly via the transdermal route, which avoids first-pass hepatic metabolism — may support healthier hepatic lipid handling in postmenopausal women. However, BHRT should not be considered a primary treatment for established NAFLD; it is best understood as one component of a comprehensive metabolic management plan that includes weight management, glycaemic control and lifestyle measures.
Fats (Lipids): Oestrogen and the Lipid Profile
Oestrogen has well-documented effects on lipid metabolism. Oral oestrogen — which undergoes first-pass hepatic metabolism — tends to raise HDL cholesterol, lower LDL cholesterol and raise triglycerides. Transdermal oestradiol, which bypasses the liver, has a more modest effect on HDL and LDL but does not raise triglycerides to the same degree. The choice of progestogen (for women with a uterus) also influences the net lipid effect.
A meta-analysis of data from randomised controlled trials examined the effects of transdermal 17β-oestradiol plus norethisterone acetate on cardiovascular disease risk factors in postmenopausal women, confirming that the transdermal route produces favourable changes in the lipid profile with a different risk-benefit balance compared with oral therapy (Lan et al., Clinical Therapeutics, 2023; PMID 37852812). A comparative study of oral and transdermal oestrogen-progestin replacement therapy found that both routes improved the lipid profile, but the magnitude and pattern of changes differed significantly (Chen et al., Menopause, 2001; PMID 11528361).
For prescribers, the practical guidance is:
- Oral oestrogen: More pronounced HDL-raising and LDL-lowering effect, but also raises triglycerides — relevant for patients with pre-existing hypertriglyceridaemia
- Transdermal oestradiol: Modest lipid benefits, no triglyceride elevation, and avoids first-pass hepatic effects — preferred for patients with hepatic concerns or hypertriglyceridaemia
- Bioidentical progesterone: Does not reverse oestrogen’s lipid benefits to the same degree as some synthetic progestins
Route Matters: Oral vs Transdermal BHRT for Metabolic Outcomes
| Parameter | Oral Oestrogen | Transdermal Oestradiol |
|---|---|---|
| Bone mineral density | Preserved | Preserved (comparable) |
| HDL cholesterol | Increases | Modest increase |
| LDL cholesterol | Decreases | Modest decrease |
| Triglycerides | Increases | No significant change |
| Hepatic first-pass effect | Significant | Minimal |
| Coagulation factors | Increases some factors | Minimal effect |
The choice between oral and transdermal BHRT should be individualised based on the patient’s metabolic profile, cardiovascular risk factors and hepatic status. Compounding allows the prescriber to select the exact hormone, dose and route for the individual patient.
Discussing BHRT for Metabolic Health with Lynnity
For GPs, gynaecologists and hormone clinics in Kuala Lumpur and the Klang Valley managing menopausal patients with concerns about bone density, liver health or lipid changes, Lynnity Compounding Pharmacy prepares bioidentical hormone formulations — including oestradiol, progesterone and testosterone — at the exact strength, form and route the prescriber specifies. Each preparation is made on a registered doctor’s prescription under Good Compounding Practice (GCP), for one named patient. Lynnity also prepares DHEA and pregnenolone formulations for patients whose prescriber identifies a clinical rationale for upstream hormone support.
To initiate a BHRT preparation, the prescriber submits a prescription specifying the hormone(s), strength, dosage form (cream, gel, capsule or sublingual liquid) and route. Lynnity’s compounding pharmacists then formulate, label and dispense the preparation with appropriate beyond-use dating and patient counselling.
Frequently Asked Questions
Can BHRT prevent osteoporosis in postmenopausal women?
Clinical evidence and systematic reviews confirm that oestrogen therapy preserves bone mineral density and reduces fracture risk when initiated within 10 years of menopause. BHRT is one option within a comprehensive bone health strategy that includes adequate calcium, vitamin D and weight-bearing exercise.
Does BHRT help with fatty liver (NAFLD) after menopause?
Oestrogen modulates hepatic lipid metabolism, and postmenopausal oestrogen decline is associated with increased NAFLD risk. Transdermal oestradiol, which avoids first-pass hepatic metabolism, may support healthier hepatic lipid handling, though BHRT is not a primary treatment for established NAFLD.
Which BHRT route is best for lipid profile management?
Transdermal oestradiol produces modest lipid benefits without raising triglycerides, making it preferable for patients with hypertriglyceridaemia or hepatic concerns. Oral oestrogen raises HDL and lowers LDL more substantially but also raises triglycerides. The choice should be individualised.
How long does it take for BHRT to affect bone density?
Bone density changes are measurable after 6–12 months of consistent therapy. The greatest benefit is seen when therapy is started within 10 years of menopause. Bone density should be monitored with DEXA scans at intervals determined by the prescribing clinician.
Does Lynnity offer BHRT for patients in Singapore?
Lynnity accepts enquiries from Singapore-based practitioners. A valid Malaysian prescription from a registered doctor is required for any compounded preparation. Singapore-based clinicians should consult with a Malaysian-registered prescriber regarding the referral pathway.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
To discuss a patient-specific BHRT formulation for managing menopause-related bone, liver or lipid changes, consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.